Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Shares Outstanding (Diluted Average) (2019 - 2025)

Autolus Therapeutics' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $266.1 million for Q2 2025.

  • For Q2 2025, Shares Outstanding (Diluted Average) rose 4.32% year-over-year to $266.1 million; the TTM value through Jun 2025 reached $266.1 million, up 4.32%, while the annual FY2024 figure was $255.2 million, 46.69% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $266.1 million in Q2 2025 per AUTL's latest filing, roughly flat from $266.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $266.1 million in Q2 2025 to a low of $72.1 million in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $176.8 million, with a median of $173.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 91.2% in 2023, then increased 4.32% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $72.1 million in 2021, then surged by 31.78% to $95.0 million in 2022, then surged by 83.11% to $173.9 million in 2023, then soared by 46.69% to $255.2 million in 2024, then grew by 4.3% to $266.1 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Shares Outstanding (Diluted Average) are $266.1 million (Q2 2025), $266.1 million (Q1 2025), and $255.2 million (Q4 2024).